Benedict v. Abbott Laboratories, Inc.

2018 IL App (1st) 180377
CourtAppellate Court of Illinois
DecidedSeptember 28, 2018
Docket1-18-0377
StatusUnpublished
Cited by3 cases

This text of 2018 IL App (1st) 180377 (Benedict v. Abbott Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Benedict v. Abbott Laboratories, Inc., 2018 IL App (1st) 180377 (Ill. Ct. App. 2018).

Opinion

2018 IL App (1st) 180377

No. 1-18-0377

Opinion filed September 13, 2018

FOURTH DIVISION

IN THE

APPELLATE COURT OF ILLINOIS

FIRST DISTRICT

CODY BENEDICT, By and Through His ) Appeal from the Circuit Court

Guardian and Conservator, Angela ) of Cook County.

Benedict, and ADDISON HAND, a ) Minor, By and Through Her Parents ) Chad and Kimberly Hand, ) ) Plaintiffs-Appellees, ) No. 2016-M1-302742

) v. ) The Honorable

) William E. Gomolinski,

ABBOTT LABORATORIES, INC. ) Judge, presiding.

) Defendant-Appellant. )

JUSTICE GORDON delivered the judgment of the court, with opinion. Justices Burke and Ellis concurred in the judgment and opinion.

OPINION

¶1 Plaintiffs, Cory Benedict and Addison Hand, allege, by and through their parents, that

they suffer from serious birth defects caused by their in utero exposure to Depakote, an No. 1-18-0377

antiepilectic drug manufactured, marketed, and sold by defendant, Abbott Laboratories, Inc.,

and ingested by plaintiffs’ mothers during pregnancy.

¶2 In this interlocutory appeal, defendant, Abbott Laboratories, Inc., appeals the trial

court’s denial of its forum non conveniens motion. Defendant argues that the trial court

abused its discretion by denying its motion (1) to dismiss the case in Illinois for refiling in

plaintiffs’ home states of Missouri and Colorado or (2), alternatively, to transfer the case

from Cook County to adjacent Lake County, where defendant is headquartered. Although

defendant’s principal place of business is in Illinois, it argues that Illinois is inconvenient.

For the following reasons, we cannot find that the trial court abused its discretion in denying

defendant’s motion, and thus, we must affirm.

¶3 BACKGROUND

¶4 Plaintiffs, Cory Benedict and Addison Hand, allege that defendant, Abbott

Laboratories, Inc., failed to provide adequate warnings regarding the risk of birth defects

from using Depakote and that, as a result, plaintiffs were born with spina bifida and neural

tube defects after their mothers ingested the drug during pregnancy.

¶5 On this appeal, plaintiffs stress that defendant’s decisions regarding product labeling

and marketing occurred in Illinois, where defendant is headquartered, whereas defendant

emphasizes that plaintiffs and their treating physicians are located outside of Illinois.

Plaintiffs, Cody Benedict and Addison Hand, reside, respectively, in Missouri and Colorado,

and their mothers were prescribed Depakote in their respective states.

¶6 Defendant is in the business of selling pharmaceutical and medical products in all 50

states, including Illinois. Specifically, defendant sold and marketed Depakote across the

country, including in Illinois and in Cook County. Defendant’s headquarters and principal

place of business are in Lake County, Illinois, while its registered agent is in adjacent Cook

County. In this action, plaintiff served defendant’s agent, CT Corporation, in Cook County.

Defendant, a Delaware corporation, concedes that venue is proper in Cook County.

¶7 Plaintiffs filed a complaint on December 23, 2016, in Cook County alleging that “the

primary compound in Depakote—valproic acid—has been established to cause severe birth

defects if taken during the first trimester of pregnancy, especially during the first twenty-

eight days of gestation when neural tube closure and other critical mid-line formations are

taking place in the cellular structure of the developing embryo.”

¶8 Plaintiffs further allege that, “[a]mong the ‘major congenital anomalies’ (i.e., birth

defects) known to result directly from first-trimester exposure to Depakote are, either singly

or in some combination with each other, spina bifida, cleft palate, cleft lip, limb and digital

deformities, facial dysmorphism, mental developmental delays, genitourinary malformations,

and heart defects.”

¶9 Plaintiffs allege that, on or before defendant began marketing Depakote in 1978,

defendant was aware of birth defects associated with it and that, even as further evidence

developed, defendant “consistently and systematically sought to minimize the risk and

downplay the dangers” and aggressively marketed the drug for additional uses.

¶ 10 Plaintiffs’ complaint alleges nine causes of action: (1) strict products liability, (2)

negligence, (3) gross negligence, (4) breach of implied warranty, (5) breach of express

warranty, (6) misrepresentation by omission, (7) fraud and misrepresentation, (8) intentional

infliction of emotional distress, and (9) negligent infliction of emotional distress.

¶ 11 In lieu of filing an answer, defendant moved on March 3, 2017, to dismiss on various

grounds, including misjoinder. Specifically, defendant argued that the claims of plaintiffs

Benedict and Hand were misjoined. The trial court did not rule on this motion prior to this

appeal, and so this issue is not before us. 1

¶ 12 On April 4, 2017, defendant moved to dismiss plaintiffs’ claims arguing that they

should be refiled in plaintiffs’ home states or, in the alternative, transferred to Lake County,

where defendant has its principal place of business.

¶ 13 While defendant’s motions were pending in this suit, eight additional plaintiffs filed

Depakote suits against defendant in Cook County. Their last names were Castillo, Counts,

Collier, Kane, McGowan, Peyton, Tasker, and Mohammed. Of these eight, two resided in

Illinois. However, the two Illinois plaintiffs (Castillo and Peyton), as well as five others

(Counts, Collier, Kane, McGowan and Tasker), chose to voluntarily dismiss their suits.

Defendant decided not to file a forum non conveniens motion against the sole remaining

plaintiff in these eight cases, namely, the Muhammad plaintiff. In its appellate brief,

defendant explained that it did not file a forum non conveniens motion in the Mohammed

case because the plaintiff’s family in that case resided in Cook County until 2014, “long after

the child plaintiff was born.”

¶ 14 On September 18, 2017, the trial court entered an order consolidating all current and

future cases concerning Depakote filed in the circuit court of Cook County “for all purposes,

excluding trial.” 2

¶ 15 On January 26, 2018, the trial court entered a memorandum opinion denying

defendant’s forum non conveniens motion. Defendant filed both (1) a motion to reconsider on

1 In its brief to this court, defendant stated: “The Circuit Court has not ruled on [defendant’s] misjoinder motion yet and therefore it is not the subject of this appeal.” 2 The order stated that the matter came “before the Court on Plaintiffs[’] and Defendant[’]s Joint Motion to Consolidate for Pre-Trial Purposes, the Court [having been] informed that more cases may be filed arising from” Depakote. 4

January 31, 2018, in the trial court and (2) a petition for leave to appeal on February 26,

2018, in the appellate court.

¶ 16 The trial court denied defendant’s motion to reconsider on April 2, 2018. The parties

then filed a joint motion in the appellate court to file a status report with a copy of the trial

court’s April 2 memorandum opinion. This court granted the motion on April 18, thereby

making the trial court’s April 2 memorandum opinion part of this appeal.

¶ 17 Since we must apply an abuse-of-discretion standard to the trial court’s forum non

conveniens decision, 3 we provide here the trial court’s findings. In its April 2 opinion, the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Deppa v. Abbott Laboratories, Inc.
2025 IL App (1st) 241795 (Appellate Court of Illinois, 2025)
Toles v. Mead Johnson & Company, LLC.
2025 IL App (5th) 231205 (Appellate Court of Illinois, 2025)
Clark Mosquito Control Products Inc. v. Lee Container Iowa, LLC.
2024 IL App (1st) 231302-U (Appellate Court of Illinois, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
2018 IL App (1st) 180377, Counsel Stack Legal Research, https://law.counselstack.com/opinion/benedict-v-abbott-laboratories-inc-illappct-2018.